^
    Apply
    A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer (NCT05433480)
    Phase 3
    Betta Pharmaceuticals Co., Ltd.
    Active, not recruiting
    Last update posted :
    07/27/2023
    Initiation :
    05/25/2022
    Primary completion :
    12/31/2023
    Completion :
    07/31/2025
    HER-2
    |
    HR positive • HER-2 negative
    |
    fulvestrant • tibremciclib (BPI-16350)